Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?

With best-selling medicines for type 2 diabetes and obesity in hand, Novo Nordisk (NYSE: NVO) isn’t content to let the chips fall where they may when it comes to patients having access to Ozempic and Wegovy. Thanks to the two drugs becoming a social phenomenon in the developed wo

admin